The utility of BRAF V600E mutation-specific antibody VE1 for the diagnosis of hairy cell leukemia

American Journal of Clinical Pathology

Volumn 143, Issue 1, 2015, Pages 120-125

  Uppal, Guldeep ^a   Ly, Vandi ^a   Wang, Zi Xuan ^a   Bajaj, Renu ^a   Solomides, Charalambos C ^a   Banks, Peter M ^b   Medeiros, L Jeffrey ^c   Peiper, Stephen C ^a   Gong, Jerald Z ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

BRAF; Hairy cell leukemia; Immunohistochemistry; VE1

Indexed keywords

ANTIBODY; B RAF KINASE; FORMIC ACID; HYDROCHLORIC ACID; UNCLASSIFIED DRUG; VE1 ANTIBODY; MONOCLONAL ANTIBODY; TUMOR MARKER;

ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FLOW CYTOMETRY; GENE MUTATION; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOMA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; B LYMPHOCYTE; BIOPSY; DIAGNOSTIC USE; GENETICS; IMMUNOLOGY; LEUKEMIA, HAIRY CELL; METABOLISM; MUTATION;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; BIOPSY; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, HAIRY CELL; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR MARKERS, BIOLOGICAL;

EID: 84923626326     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPQLQ89VXTVWKN     Document Type: Article

References (23)

1. Foucar K, Falini B, Catovsky D, et al. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008: 188-190.
2. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011; 364: 2305-2315.
3. Machnicki MM, Stoklosa T. BRAF-A new player in hematological neoplasms. Blood Cells Mol Dis. 2014; 53: 77-83.
4. Verma S, Greaves WO, Ravandi F, et al. Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol. 2012; 138: 153-156.
5. Langabeer SE, Quinn F, O'Brien D, et al. Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. Leuk Res. 2012; 36: 483-484.
6. Boyd EM, Bench AJ, van 't Veer MB, et al. High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies. Br J Haematol. 2011; 155: 609-612.
7. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471: 467-472.
8. Andrulis M, Penzel R, Weichert W, et al. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012; 36: 1796-1800.
9. Akarca AU, Shende VH, Ramsay AD, et al. BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukemia. Br J Haematol. 2013; 162: 848-851.
10. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-954.
11. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-Analysis. Cancer. 2012; 118: 1764-1773.
12. Ardekani GS, Jafarnejad SM, Tan L, et al. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-Analysis. PLoS One. 2012; 10: e47054.
13. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011; 29: 3574-3579.
14. Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011; 6: e17948.
15. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010; 116: 1919-1923.
16. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012; 120: 2700-2703.
17. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011; 122: 11-19.
18. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012; 36: 844-850.
19. Arcaini L, Zibellini S, Boveri E, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012; 119: 188-191.
20. Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012; 119: 3330-3332.
21. Schnittger S, Bacher U, Haferlach T, et al. Development and validation of a real-Time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. Blood. 2012; 119: 3151-3154.
22. Tschernitz S, Flossbach L, Bonengel M, et al. Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias. Br J Haematol. 2014; 165: 529-533.
23. Jebaraj BM, Kienle D, Buhler A, et al. BRAF mutations in chronic lymphocytic leukemia. Leuk Lymphoma. 2013; 54: 1177-1182.